Next-Generation Glycemic Control Therapeutics
|発行||Greystone Research Associates||商品コード||337816|
|次世代血糖コントロール薬 Next-Generation Glycemic Control Therapeutics|
|出版日: 2015年08月24日||ページ情報: 英文||
As the number of patients diagnosed with diabetes continues to climb worldwide, drug developers and researchers are attempting for find more effective ways to control glucose levels, particularly for Type 2 diabetics. These efforts have led to a growing list of GLP-1 agonists and DPP-4 inhibitors that have been approved or are in late stage clinical development. New medicines based on novel therapeutic moieties and potentially unique benefits are attracting attention and research investment. The result is an evolving therapeutic landscape that is providing clinicians and patients with new ways to manage their diabetes. For market participants, product positioning and prescriber training will become increasingly important as competitive threats remain fluid.
The value we provide to our clients and subscribers is best illustrated by our ability to consistently provide strategic direction and market knowledge that contributes to their tactical and strategic decision process.
A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.
The market for glycemic control continues to grow globally at rates that are alarming to public health officials. Over the past decade, prevalence of diabetes among adults has increased by 33 percent. In the United States, approximately 6 percent of the population (i.e., 16 million people) has diabetes and it is the fourth-leading cause of death by disease. Among Americans in their thirties, diabetes has increased by 70 percent in the past 10 years. Each year, approximately 798,000 people are diagnosed with diabetes. However, one-third of the people afflicted are currently undiagnosed.
Our reports are carefully researched and written to provide timely and insightful analysis of key factors and developments shaping the commercial marketplace. The focused nature of our publications is designed to allow readers to identify emerging demand and growth opportunities in selected markets. Numerous charts, tables and graphs complement the text, with evaluations and assessments of current and probable future market developments, technology issues and business factors - information necessary to compete effectively in the global marketplace.